Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.69 |
| ▸ | BRAF | P15056 | 3/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | TEK | Q02763 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520991 | 0.91 | KDR (0.69) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2523521 | 0.90 | KDR (0.67) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2518692 | 0.87 | KDR (0.65) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2519129 | 0.86 | KDR (0.75) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL3486263 | 0.85 | KDR (0.84) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2513777 | 0.85 | KDR (0.76) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2514277 | 0.84 | KDR (0.83) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2514369 | 0.84 | KDR (0.80) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL2513810 | 0.84 | KDR (0.79) | KDRBRAFPDGFRBKITFGFR1 | |
| SCHEMBL12206497 | 0.84 | KDR (0.82) | KDRBRAFPDGFRBKITFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | KDR 1/4885BRAF 4/4885PDGFRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.